Wedbush restated their outperform rating on shares of Nuvation Bio (NYSE:NUVB – Get Rating) in a research report sent to investors on Thursday, Benzinga reports. Wedbush currently has a $5.00 target price on the stock.
Separately, Jefferies Financial Group cut shares of Nuvation Bio from a buy rating to a hold rating and cut their price objective for the company from $5.00 to $2.00 in a report on Friday, January 6th. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat, Nuvation Bio presently has a consensus rating of Moderate Buy and a consensus price target of $4.00.
Nuvation Bio Stock Down 2.4 %
NUVB opened at $1.64 on Thursday. Nuvation Bio has a fifty-two week low of $1.55 and a fifty-two week high of $6.02. The company has a fifty day moving average of $2.11 and a two-hundred day moving average of $2.12.
Institutional Trading of Nuvation Bio
Nuvation Bio Company Profile
Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation; NUV-569, a differentiated oral small molecule selective inhibitor of the Wee1 kinase for DNA damage repair; NUV-1182, an adenosine receptor inhibitor; and drug-drug conjugate (DDC) platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to anti-cancer warheads of existing drugs, as well as PARP inhibitor to address ER+ breast and ovarian cancer.
- Get a free copy of the StockNews.com research report on Nuvation Bio (NUVB)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for Nuvation Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvation Bio and related companies with MarketBeat.com's FREE daily email newsletter.